Indegene Ltd
Incorporated in 1998, Indegene Ltd provides
solutions consisting of analytics, technology
and commercial, medical, regulatory and
safety services to life science and health
care organizations[1]
- Market Cap ₹ 12,438 Cr.
- Current Price ₹ 516
- High / Low ₹ 597 / 414
- Stock P/E 58.7
- Book Value ₹ 86.4
- Dividend Yield 0.44 %
- ROCE 14.3 %
- ROE 10.7 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 17.3%
- Debtor days have improved from 119 to 86.2 days.
- Company's working capital requirements have reduced from 91.9 days to 50.8 days
Cons
- Company has a low return on equity of 12.0% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 282 | 334 | 511 | 837 | 1,006 | 1,046 | 1,094 | 1,221 | |
| 230 | 249 | 361 | 668 | 828 | 878 | 913 | 972 | |
| Operating Profit | 53 | 86 | 150 | 169 | 178 | 168 | 180 | 248 |
| OPM % | 19% | 26% | 29% | 20% | 18% | 16% | 17% | 20% |
| 12 | -24 | 30 | 28 | 37 | 50 | 90 | 78 | |
| Interest | 1 | 3 | 4 | 3 | 6 | 7 | 6 | 9 |
| Depreciation | 4 | 13 | 18 | 24 | 32 | 31 | 26 | 36 |
| Profit before tax | 59 | 46 | 159 | 170 | 177 | 181 | 238 | 281 |
| Tax % | 14% | 30% | 17% | 22% | 26% | 24% | 24% | 25% |
| 51 | 32 | 132 | 133 | 130 | 138 | 181 | 212 | |
| EPS in Rs | 324.22 | 202.30 | 843.58 | 755.26 | 5.87 | 6.20 | 7.55 | 8.80 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 26% | 26% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 7% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 18% |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 12% |
| Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.31 | 0.30 | 0.30 | 0.40 | 44 | 44 | 48 | 48 |
| Reserves | 158 | -3 | 254 | 650 | 751 | 909 | 1,840 | 2,032 |
| 106 | 362 | 23 | 44 | 51 | 38 | 27 | 70 | |
| 57 | 72 | 96 | 156 | 191 | 228 | 234 | 332 | |
| Total Liabilities | 322 | 431 | 373 | 850 | 1,038 | 1,220 | 2,150 | 2,482 |
| 8 | 31 | 41 | 72 | 78 | 56 | 53 | 113 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 12 |
| Investments | 134 | 251 | 83 | 203 | 400 | 624 | 975 | 1,318 |
| 180 | 148 | 249 | 575 | 559 | 540 | 1,119 | 1,039 | |
| Total Assets | 322 | 431 | 373 | 850 | 1,038 | 1,220 | 2,150 | 2,482 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 62 | 90 | 53 | 38 | 82 | 176 | 129 | 346 | |
| -70 | -51 | -34 | -267 | -51 | -189 | -824 | -270 | |
| 15 | -18 | -37 | 245 | -17 | -16 | 717 | -63 | |
| Net Cash Flow | 8 | 20 | -18 | 16 | 14 | -29 | 22 | 13 |
| Free Cash Flow | 60 | 84 | 35 | 17 | 66 | 166 | 112 | 302 |
| CFO/OP | 145% | 122% | 52% | 44% | 70% | 134% | 111% | 159% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65 | 65 | 125 | 152 | 145 | 132 | 140 | 86 |
| Inventory Days | ||||||||
| Days Payable | ||||||||
| Cash Conversion Cycle | 65 | 65 | 125 | 152 | 145 | 132 | 140 | 86 |
| Working Capital Days | 16 | -12 | 76 | 103 | 113 | 104 | 121 | 51 |
| ROCE % | 28% | 49% | 36% | 24% | 18% | 17% | 14% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| $1M+ Clients Count |
|
|||||
| Active Client Relationships Count |
||||||
| Total Employees Count |
||||||
| $25M+ Strategic Clients Count |
||||||
| Top 20 Customer Revenue INR Mn |
||||||
| Revenue per Employee USD |
||||||
| Net Revenue Retention % |
||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 18 Jul
-
Letter To Shareholders In Relation To Annual Report Of The Company For The Financial Year 2025-26
17 Jul - Indegene schedules 28th AGM on 13 August 2026 and shares FY26 annual report link.
-
Business Responsibility and Sustainability Reporting (BRSR)
17 Jul - Indegene filed its FY 2025-26 BRSR as part of the annual report.
-
Reg. 34 (1) Annual Report.
17 Jul - Indegene issued FY2025-26 annual report, AGM notice for 13 August 2026, and ₹2.25 final dividend proposal.
- Notice Of The 28Th Annual General Meeting Of The Company 17 Jul
Annual reports
Concalls
-
May 2026TranscriptAI SummaryPPT
-
May 2026Transcript PPT REC
-
Apr 2026TranscriptAI SummaryPPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT
-
Oct 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Mar 2025TranscriptAI SummaryPPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptPPTREC
Business Overview:[1]
IL is a digital-first healthcare and technology company. It helps bio pharmaceutical, emerging biotech and medical device companies to develop products and get them to market. Company brings together healthcare domain expertise, technology and an agile operating model to provide diverse solutions for patients and physicians.